Biomimetic and Materials-Potentiated Cell Engineering for Cancer Immunotherapy.
biomimetic engineering
cancer immunotherapy
immune cell
materials-potentiated cell engineering
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
30
01
2022
revised:
17
03
2022
accepted:
25
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
In cancer immunotherapy, immune cells are the main force for tumor eradication. However, they appear to be dysfunctional due to the taming of the tumor immunosuppressive microenvironment. Recently, many materials-engineered strategies are proposed to enhance the anti-tumor effect of immune cells. These strategies either utilize biomimetic materials, as building blocks to construct inanimate entities whose functions are similar to natural living cells, or engineer immune cells with functional materials, to potentiate their anti-tumor effects. In this review, we will summarize these advanced strategies in different cell types, as well as discussing the prospects of this field.
Identifiants
pubmed: 35456568
pii: pharmaceutics14040734
doi: 10.3390/pharmaceutics14040734
pmc: PMC9024915
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Commun. 2020 Mar 20;11(1):1508
pubmed: 32198351
Adv Mater. 2020 Oct;32(39):e2003368
pubmed: 32812291
ACS Cent Sci. 2018 Dec 26;4(12):1633-1641
pubmed: 30648147
Adv Mater. 2021 Apr;33(14):e2008061
pubmed: 33634897
J Clin Invest. 2005 Jun;115(6):1616-26
pubmed: 15931392
J Control Release. 2020 Apr 10;320:421-430
pubmed: 32027936
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Cancer Cell. 2021 Jul 12;39(7):945-957.e10
pubmed: 34019807
Clin Cancer Res. 2008 Jun 15;14(12):3966-74
pubmed: 18559619
ACS Nano. 2021 Sep 28;15(9):15166-15179
pubmed: 34469109
Oncotarget. 2011 Dec;2(12):1155-64
pubmed: 22201704
Mol Immunol. 2018 Jun;98:13-18
pubmed: 29525074
Cancer Cell. 2021 Oct 11;39(10):1361-1374.e9
pubmed: 34478639
Cancer Immunol Immunother. 2009 Jan;58(1):1-14
pubmed: 18719915
ACS Omega. 2017 Mar 31;2(3):937-945
pubmed: 28393131
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):E2776-E2785
pubmed: 28283662
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
ACS Cent Sci. 2020 Mar 25;6(3):382-389
pubmed: 32232138
Angew Chem Int Ed Engl. 2020 Jul 13;59(29):11892-11897
pubmed: 32307868
Small. 2021 Nov;17(45):e2103463
pubmed: 34761524
Nat Rev Immunol. 2017 Apr;17(4):248-261
pubmed: 28287106
Curr Hematol Rep. 2003 Nov;2(6):522-7
pubmed: 14561398
Adv Mater. 2020 Nov;32(47):e2004853
pubmed: 33089578
Nat Commun. 2019 Jan 16;10(1):240
pubmed: 30651559
J Am Chem Soc. 2017 Sep 13;139(36):12450-12458
pubmed: 28829594
Nat Rev Immunol. 2003 Dec;3(12):973-83
pubmed: 14647479
Nat Rev Cancer. 2021 May;21(5):298-312
pubmed: 33750922
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Sep-Oct;5(5):469-83
pubmed: 23633389
Cancer Res. 2015 Jan 15;75(2):296-305
pubmed: 25432172
ACS Appl Mater Interfaces. 2020 Dec 23;12(51):56731-56740
pubmed: 33290037
Adv Healthc Mater. 2018 May;7(9):e1701163
pubmed: 29283226
Oncoimmunology. 2014 Jan 1;3(1):e27561
pubmed: 24744977
Nano Lett. 2018 Sep 12;18(9):5716-5725
pubmed: 30063143
Theranostics. 2016 Sep 2;6(11):2000-2014
pubmed: 27698936
Cancer Immunol Immunother. 2017 Sep;66(9):1229-1241
pubmed: 28501941
Crit Rev Oncol Hematol. 2016 Nov;107:100-110
pubmed: 27823637
Cell Rep. 2020 Dec 15;33(11):108499
pubmed: 33326787
Biomaterials. 2018 Oct;181:35-52
pubmed: 30071380
J Am Chem Soc. 2020 Jul 22;142(29):12579-12584
pubmed: 32658476
Curr Biol. 2017 Jul 24;27(14):2065-2077.e6
pubmed: 28669759
Adv Mater. 2021 Aug;33(33):e2102322
pubmed: 34247428
Biomaterials. 2017 Feb;118:16-26
pubmed: 27940380
Biomed Pharmacother. 2021 Jul;139:111605
pubmed: 33901872
Cancers (Basel). 2019 Apr 01;11(4):
pubmed: 30939820
J Biol Chem. 2012 Dec 14;287(51):42664-74
pubmed: 23091059
Bioconjug Chem. 2018 Dec 19;29(12):4160-4167
pubmed: 30395444
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
Nat Commun. 2021 Oct 8;12(1):5911
pubmed: 34625545
Biomaterials. 2014 Jan;35(1):269-277
pubmed: 24099710
Nanomicro Lett. 2021 Jan 4;13(1):31
pubmed: 34138236
J Exp Med. 2021 Nov 1;218(11):
pubmed: 34559187
J Immunol Res. 2018 Sep 17;2018:4054815
pubmed: 30306093
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
J Exp Med. 2005 Aug 15;202(4):493-503
pubmed: 16087711
Sci Adv. 2020 Nov 20;6(47):
pubmed: 33219021
Future Oncol. 2012 Oct;8(10):1273-99
pubmed: 23130928
Biomater Sci. 2018 Sep 25;6(10):2714-2725
pubmed: 30151523
Nat Med. 2010 Sep;16(9):1035-41
pubmed: 20711198
Adv Mater. 2019 Apr;31(15):e1807211
pubmed: 30803083
J Immunol. 2010 Jun 1;184(11):6529-36
pubmed: 20421638
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Nat Biotechnol. 2018 Sep;36(8):707-716
pubmed: 29985479
Biomaterials. 2012 Aug;33(23):5776-87
pubmed: 22594972
Small. 2019 Oct;15(42):e1902636
pubmed: 31468667
Cancer Lett. 2017 Apr 1;390:188-200
pubmed: 28089834
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:61-79
pubmed: 28061688
Adv Mater. 2021 Aug;33(33):e2101110
pubmed: 34235790
Cancer Immunol Res. 2018 Jul;6(7):812-824
pubmed: 29720380
Front Immunol. 2017 Mar 08;8:248
pubmed: 28337200
Trends Immunol. 2017 Jun;38(6):432-443
pubmed: 28499492
Semin Cell Dev Biol. 2019 Feb;86:77-88
pubmed: 29454038
Front Immunol. 2019 May 03;10:931
pubmed: 31130945
Nat Nanotechnol. 2012 Jun 03;7(7):428-32
pubmed: 22659609
Adv Mater. 2017 Apr;29(16):
pubmed: 28199033
Blood. 2010 May 27;115(21):4293-301
pubmed: 20233969
Semin Hematol. 2007 Jan;44(1):15-23
pubmed: 17198843
Sci Transl Med. 2021 Mar 31;13(587):
pubmed: 33790024
Cell. 2021 Jul 22;184(15):3998-4015.e19
pubmed: 34157302
Angew Chem Int Ed Engl. 2014 Mar 10;53(11):2893-8
pubmed: 24519972
Adv Mater. 2018 May;30(22):e1707112
pubmed: 29656492
Trends Biotechnol. 2014 Sep;32(9):456-65
pubmed: 24998519
Adv Mater. 2019 May;31(19):e1901179
pubmed: 30924234
Sci Transl Med. 2020 Nov 25;12(571):
pubmed: 33239389
Angew Chem Int Ed Engl. 2020 Feb 24;59(9):3732-3738
pubmed: 31834981
Signal Transduct Target Ther. 2021 Feb 23;6(1):75
pubmed: 33619259
Nat Rev Immunol. 2005 Jul;5(7):532-45
pubmed: 15999094
J Clin Oncol. 2010 Feb 20;28(6):955-9
pubmed: 20085940
Nat Nanotechnol. 2019 Dec;14(12):1129-1134
pubmed: 31740796
Biomaterials. 2018 Mar;159:161-173
pubmed: 29329051
Nature. 2020 Sep;585(7824):277-282
pubmed: 32879489
Theranostics. 2017 Aug 17;7(14):3504-3516
pubmed: 28912891
Nat Commun. 2019 Jul 19;10(1):3199
pubmed: 31324770
Sci Adv. 2020 Apr 29;6(18):eaaz6579
pubmed: 32494680
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74
pubmed: 14762166
Blood. 2009 Sep 17;114(12):2417-26
pubmed: 19605850
Front Immunol. 2015 Nov 30;6:605
pubmed: 26648934
Biomaterials. 2021 Dec;279:121228
pubmed: 34717198
Am J Adv Drug Deliv. 2018;6(1):21-32
pubmed: 30197907
Theranostics. 2019 Sep 21;9(23):6936-6948
pubmed: 31660078
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Bioconjug Chem. 2019 Mar 20;30(3):552-560
pubmed: 30779553
Adv Mater. 2021 Apr;33(17):e2100616
pubmed: 33760313
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Blood. 1995 Jan 1;85(1):139-45
pubmed: 7803791
J Control Release. 2018 Nov 28;290:141-149
pubmed: 30312720
Nat Clin Pract Oncol. 2005 Mar;2(3):115
pubmed: 16264884
Curr Opin Hematol. 2001 May;8(3):161-4
pubmed: 11303149
Cancer Res. 2010 Mar 15;70(6):2245-55
pubmed: 20179192
J Biol Chem. 2018 Jul 13;293(28):11143-11153
pubmed: 29853638
Nat Commun. 2017 Oct 3;8(1):770
pubmed: 28974671
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
ACS Appl Mater Interfaces. 2016 Nov 9;8(44):29950-29959
pubmed: 27754664
Small. 2019 May;15(22):e1900903
pubmed: 31026116
Biomater Sci. 2019 Mar 26;7(4):1345-1357
pubmed: 30698174
EMBO J. 2009 Mar 4;28(5):466-76
pubmed: 19177148
Adv Mater. 2020 Jun;32(22):e2000020
pubmed: 32319126
Nat Commun. 2019 Nov 14;10(1):5165
pubmed: 31727883
Nat Commun. 2021 Oct 8;12(1):5908
pubmed: 34625564
J Immunol. 2005 Jan 15;174(2):1073-80
pubmed: 15634932
Nat Immunol. 2020 Aug;21(8):835-847
pubmed: 32690952
Nat Rev Cancer. 2016 Jan;16(1):7-19
pubmed: 26694935
Biomaterials. 2012 Aug;33(22):5584-92
pubmed: 22575830
Immunotherapy. 2011 Apr;3(4 Suppl):6-11
pubmed: 21524159
Front Immunol. 2021 Jul 08;12:686031
pubmed: 34305918
J Am Chem Soc. 2021 Jan 13;143(1):232-240
pubmed: 33356224
Front Immunol. 2019 Oct 29;10:2393
pubmed: 31736936
Oncotarget. 2017 Apr 18;8(16):27252-27262
pubmed: 28460478
Adv Mater. 2020 Jul;32(30):e2001808
pubmed: 32538494
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Angew Chem Int Ed Engl. 2020 Jul 13;59(29):12022-12028
pubmed: 32246555
Angew Chem Int Ed Engl. 2021 Feb 15;60(7):3603-3610
pubmed: 33314603